Wells Fargo Adds ViroPharma (VPHM) to Its Priority List
Tweet Send to a FriendGet Alerts VPHM Hot Sheet
Price: $25.88 +1.01%
Rating Summary:
11 Buy, 8 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
11 Buy, 8 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade VPHM Now!
Wells Fargo today added ViroPharma Inc. (Nasdaq: VPHM) to its priority stock list, calling the stock its highest conviction mid-cap biotech idea.
Analysts said they have continued conviction that there is a significant discount between the stock's current valuation and the company's strong fundamentals.
"We believe that the revenues from the Cinryze franchise will continue to grow consistently based on the solid HAE demand metrics. Additionally, with no other companies yet pursuing an IV C1esterase for prophylaxis, the efficacy of subQ C1esterase inhibitors unproven and their potential convenience advantages over Cinryze likely modest, VPHM having the most promising subQ C1esterase anyway, and the general reticence of patients on effective orphan therapies to change, we believe concerns over post2015 Cinryze market share erosion are substantially overstated," wrote an analyst at the bank.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analysts said they have continued conviction that there is a significant discount between the stock's current valuation and the company's strong fundamentals.
"We believe that the revenues from the Cinryze franchise will continue to grow consistently based on the solid HAE demand metrics. Additionally, with no other companies yet pursuing an IV C1esterase for prophylaxis, the efficacy of subQ C1esterase inhibitors unproven and their potential convenience advantages over Cinryze likely modest, VPHM having the most promising subQ C1esterase anyway, and the general reticence of patients on effective orphan therapies to change, we believe concerns over post2015 Cinryze market share erosion are substantially overstated," wrote an analyst at the bank.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- UPDATE: Leerink Swann Upgrades Bristol-Myers Squibb Co. (BMY) to Outperform
- Topeka Capital Starts Laredo Petroleum (LPI) at Buy, Assets 'Undervalued'
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Wells Fargo
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
